Spots Global Cancer Trial Database for Phase II AK Study in Organ Transplant Patients

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Phase II AK Study in Organ Transplant Patients

Official Title: A Multicentre, Randomised, Double-Blind, Placebo Controlled, Phase II Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable Implants of Afamelanotide (CUV1647) for the Prophylactic Treatment of Pre-Cancerous Skin Lesions of the Head, Forearms and Hands in Immune Compromised, Organ Transplant Patients.

Study ID: NCT00829192

Conditions

Actinic Keratoses

Carcinoma, Squamous Cell

Organ Transplant Recipients

Interventions

Afamelanotide (CUV1647)

Placebo

Study Description

Brief Summary: The purpose of this study is to determine whether afamelanotide (CUV1647) is effective in reducing the number of actinic keratoses and squamous cell carcinomas developing in immune compromised organ transplant recipients, who are at particularly high risk, over a 24 month test period. The number of lesions formed on the head, hands and forarms will be monitored over this 24 month test period.

Detailed Description: